Anti-Climax
AUSSIE BIOTECHS COMBINE FORCES A merger has been announced between two listed Australian biotechnology companies, Peptech and EvoGenix. EvoGenix shareholders approved the merger proposal to form a yet-to-be renamed company from the two antibody therapeutics companies. It is expected that the combined funds of the merged companies will be $167 million in cash, which…

